The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer
出版年份 2022 全文链接
标题
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer
作者
关键词
-
出版物
CANCER TREATMENT REVIEWS
Volume 113, Issue -, Pages 102500
出版商
Elsevier BV
发表日期
2022-12-25
DOI
10.1016/j.ctrv.2022.102500
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- 162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer
- (2022) E.P. Hamilton et al. ANNALS OF ONCOLOGY
- Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)
- (2022) Véronique Diéras et al. CANCER RESEARCH
- Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
- (2022) Eleonora Nicolò et al. CANCER TREATMENT REVIEWS
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
- (2022) Javier Cortés et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers
- (2022) Jinfeng Yu et al. Frontiers in Molecular Biosciences
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- (2022) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial
- (2022) K. Goto et al. ANNALS OF ONCOLOGY
- LBA72 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial
- (2022) M.F. Mosele et al. ANNALS OF ONCOLOGY
- 1205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen
- (2022) G.Y. Ku et al. ANNALS OF ONCOLOGY
- A Phase 1/1b Trial of PD 0332991 (Palbociclib) and T-DM1 in HER2 Positive Advanced Breast Cancer after Trastuzumab and Taxane Therapy
- (2021) Barbara Haley et al. Clinical Breast Cancer
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
- (2021) Salvatore Siena et al. LANCET ONCOLOGY
- 202TiP ASTEFANIA: A phase III study of trastuzumab emtansine (T-DM1) plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy
- (2021) P. Schmid et al. ANNALS OF ONCOLOGY
- 328TiP Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09
- (2021) S.M. Tolaney et al. ANNALS OF ONCOLOGY
- LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer
- (2021) C. Saura Manich et al. ANNALS OF ONCOLOGY
- Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors.
- (2021) Manish Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).
- (2021) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
- (2021) Mark D. Pegram et al. MOLECULAR CANCER THERAPEUTICS
- Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer
- (2021) Bob T. Li et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
- (2021) Laura M. Spring et al. npj Breast Cancer
- Proton pump inhibitors interfere with the anti-tumor potency of RC48ADC
- (2021) Xinling Zhang et al. TOXICOLOGY IN VITRO
- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
- (2020) Shanu Modi et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2-Low Breast Cancer: Pathological and Clinical Landscape
- (2020) Paolo Tarantino et al. JOURNAL OF CLINICAL ONCOLOGY
- A first in-human study of A166 in patients with locally advanced/metastatic solid tumors which are HER2-positive or HER2-amplified who did not respond or stopped responding to approved therapies.
- (2020) Yongheng Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human phase I study of ALT-P7, a HER2-targeting antibody-drug conjugate in patients with HER2-positive advanced breast cancer.
- (2020) Yeon Hee Park et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors.
- (2020) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC).
- (2020) Adrienne Gropper Waks et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand
- (2020) Natalia Buza ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
- (2020) Andrea Sartore-Bianchi et al. ESMO Open
- Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer
- (2019) Manish A. Shah et al. Gastric Cancer
- Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE
- (2019) Edith A. Perez et al. CANCER
- Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
- (2019) K L Jhaveri et al. ANNALS OF ONCOLOGY
- Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10
- (2019) Jame Abraham et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
- (2018) Sarika Jain et al. BREAST CANCER RESEARCH AND TREATMENT
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
- (2018) Bob T. Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
- (2018) Amanda N. Fader et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer.
- (2018) Cristina Saura et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression
- (2017) Gulden Menderes et al. GYNECOLOGIC ONCOLOGY
- Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads
- (2017) Joanna C. Masters et al. INVESTIGATIONAL NEW DRUGS
- Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)
- (2017) Matthew Sung et al. MOLECULAR CANCER THERAPEUTICS
- HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
- (2017) et al. Cancers
- Real-Time Analysis on Drug-Antibody Ratio of Antibody-Drug Conjugates for Synthesis, Process Optimization, and Quality Control
- (2017) Yubo Tang et al. Scientific Reports
- TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
- (2016) María F. Mercogliano et al. CLINICAL CANCER RESEARCH
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials
- (2016) Susan D Richman et al. JOURNAL OF PATHOLOGY
- Lung cancer patients withHER2mutations treated with chemotherapy andHER2-targeted drugs: results from the European EUHER2 cohort
- (2015) J. Mazières et al. ANNALS OF ONCOLOGY
- Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
- (2015) F. Loganzo et al. MOLECULAR CANCER THERAPEUTICS
- Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
- (2013) Mario Giuliano et al. Breast Care
- HER2 testing in gastric cancer: a practical approach
- (2012) Josef Rüschoff et al. MODERN PATHOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches
- (2012) Osamu Matsuno RESPIRATORY RESEARCH
- Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
- (2007) Ravi V. J. Chari ACCOUNTS OF CHEMICAL RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search